title: Aldosterone, a new appreciation of its role in heart failure.
abstract: Understanding of the role, triggers, and impact of the renin-angiotensin-aldosterone system in cardiovascular disease has significantly broadened. In recent years substantial discoveries have been made regarding the pathophysiology of heart failure, particularly in the area of neurohormonal activation. New interest in therapy with aldosterone antagonists was stimulated by results of a 2-year study of 1663 patients with heart failure that showed a 30% relative risk reduction of death among patients given a subhemodynamic dosage of spironolactone, a nonselective aldosterone antagonist, compared with placebo, in addition to standard therapy of diuretics, angiotensin-converting enzyme inhibitors, beta-blockers, and digitalis.
authors.affiliation: Pharmacia Global Healthcare Resources, Skokie, Illinois 60077, USA.
authors.forename: A J
authors.initials: AJ
authors.lastname: Cha
authors.forename: S E
authors.initials: SE
authors.lastname: Malecha
authors.forename: K W
authors.initials: KW
authors.lastname: Judge
mesh_terms: D000450:Aldosterone / Q000096:biosynthesis / Q000097:blood*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D012084:Renin-Angiotensin System / Q000502:physiology*; D013148:Spironolactone / Q000627:therapeutic use*; D016019:Survival Analysis; D014661:Vasoconstriction / Q000502:physiology
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000450:Aldosterone